Tagged with Pharmaceuticals

Ireland Iwer Baecker, MD of Bayer Ireland, outlines the Irish affiliate’s impressive growth in the past few years, the strategy of New Bayer and how it comes into play in Ireland, as well as how Ireland’s small size is not a constraint but rather a huge opportunity to be taken advantage…

Mexico This chart gives an insight into the phenomenal importance of the pharmaceutical industry to Mexico, in terms of both monetary value and employment created. Public, private, and out of pocket healthcare coverage in Mexico. The growth of the Mexican pharma industry by patented, generic and OTC segments. API Manufacturing compared…

Mexico Francisco Rodriguez, general manager Mexico and Latin America at Mundipharma, provides an overview of the customized market approach that has allowed the company to establish itself as the partner of choice of the medical and regulatory authorities in the pain management field, and how Mundipharma now looks at replicating similar…

Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…

Philippines Alvin So, Bayer Consumer Health Country Division Head, discusses Bayer’s commitment in Consumer Health in the Philippines. He also discusses his vision for the future, including expanding the product portfolio in the country and continuing to be the partner of choice for the Filipino population. When you assumed the position…

Singapore In an exclusive interview with Richard Saynor at GSK, he outlines the growth of the CEP portfolio in emerging markets and highlights the opportunities and challenges in the region, as well as the strategic benefits of operating in Singapore.   Even though our key medicines have many generic competitors, their…

Switzerland It is tempting to characterize Switzerland’s global pharma and life science hotspots as beginning and ending with Basel – home of industry giants Roche and Novartis. However, Zurich, Geneva, and even tiny Zug are all now staking serious claims for global recognition in this area. “Zurich is the world’s smallest…

Mexico Mario Sturion, the recently appointed general manager of Janssen Mexico, assesses the specific challenges and opportunities of the Mexican health system and explains how a customized market access approach has been critical to Janssen’s success in a country noteworthy for the complexity of its public health system. You took over…

Philippines J. de Ruyter “Toto” C. Oroceo, President and General Manager of Delex Pharma International Inc. (DPII), and his team discuss the company’s rapid growth in the Philippines since 2013, the key areas driving success for the company as well as their plans to venture into manufacturing and expanding their business…

Philippines J. de Ruyter “Toto” C. Oroceo, President and General Manager of Delex Pharma International Inc. (DPII), and his team discuss the company’s rapid growth in the Philippines since 2013, the key areas driving success for the company as well as their plans to venture into manufacturing and expanding their business…

Singapore HGP Partner and Director of Asia, Ming Chua on the company’s reasons for using Singapore as the first point of entry into Asia, while highlighting the expansion of the country’s biomedical sciences sector as a major factor in HGP’s consistent year-on-year growth. He also speaks to the company’s qualities in…

Switzerland Bernhard Neidhart, head of Office for Economy and Labor in Zug, introduces us to the Canton of Zug and explains how the region became a hotspot for pharma.   To begin Dr. Neidhart, could you please introduce us to the Canton of Zug? How does Zug’s “value proposition” compare to…